Search Within

Hematology-Oncology Fellows

Formats
  1. Meeting Abstract (2134)
  2. Journal Article (1760)
  3. Review (262)
  4. Editorial (133)
  5. Research Letter (85)
  6. Correspondence (45)
  7. Book Section (31)
  8. Guidelines (25)
  9. Miscellaneous (14)
  10. Conference Paper (8)
Groups
  1. Department of Medicine (4178)
  2. Weinberg Fellows (2759)
  3. Hematologic Malignancies, Division of (2494)
  4. Solid Tumor Oncology Division (2427)
  5. Center for Hematologic Malignancies (1946)
  6. GSK Faculty (1881)

More Groups

People
  1. Sergio Giralt (433)
  2. Michael Scordo (389)
  3. Gunjan Shah (348)
  4. Miguel-Angel Perales (338)
  5. Sean Devlin (289)
  6. Marcel Van Den Brink (263)

More People

Years
  1. 2025 (349)
  2. 2024 (636)
  3. 2023 (600)
  4. 2022 (628)
  5. 2021 (503)
  6. 2020 (496)

More Years

Publications
  1. Blood (713)
  2. Journal of Clinical Oncology (685)
  3. Annals of Oncology (133)
  4. Clinical Cancer Research (131)
  5. Cancer Research (126)
  6. Biology of Blood and Marrow Transplantation (124)

More Publications

Publishers
  1. American Society of Hematology (806)
  2. American Society of Clinical Oncology (774)
  3. Elsevier Inc. (544)
  4. Nature Publishing Group (359)
  5. American Association for Cancer Research (352)
  6. Oxford University Press (211)

More Publishers

Results (4497)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Carter, J.; Dogan, A.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; Abramson, J. S.; Batlevi, C. L.; Joffe, E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Circulating tumor cells (CTCs) with small-cell like pathology are prevalent in metastatic castration-resistant prostate cancer (mCRPC) and show selective pharmacodynamic reductions in patients treated with platinum but not ARSI or taxane
    Meeting Abstract

    Scher, H. I.; Jendrisak, A.; Gill, A.; Barnett, E.; Gopalan, A.; Zaidi, S.; Benoliel, H.; Carbone, E.; Byun, J.; Schonhoft, J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Acquired resistance to PD-1 blockade in NSCLC
    Meeting Abstract

    Schoenfeld, A. J.; Rizvi, H.; Memon, D.; Luo, J.; Preeshagul, I. R.; Sauter, J. L.; Plodkowski, A. J.; Vanderbilt, C.; Miller, M. L.; Hellmann, M. D.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Gastric-type adenocarcinoma of the cervix: Genomic drivers and clinical outcomes
    Meeting Abstract

    Sassine, D.; Straubhar, A. M.; Aghajanian, C.; Alektiar, K. M.; Broach, V.; Cadoo, K. A.; Jewell, E. L.; Kyi, C.; Leitao, M. M.; Mueller, J. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Association of immune-related adverse events (irAEs) with improved clinical outcome in sarcoma patients treated with immune checkpoint blockade (ICB)
    Meeting Abstract

    Rosenbaum, E.; Seier, K.; Kelly, C. M.; Kiesler, H.; Martindale, M.; Nicholls, C.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Clinical characteristics, genomic features, and recurrence risk of early-stage MET exon 14 mutant non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Recondo, G.; Guo, R.; Cravero, P.; Ricciuti, B.; Falcon, C.; Vokes, N.; Kris, M. G.; Leonardi, G. C.; Lamberti, G.; Nguyen, T.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • High-dose osimertinib for CNS progression in EGFR+ non-small cell lung cancer (NSCLC): A multi-institutional experience
    Meeting Abstract

    Piper-Vallillo, A.; Rotow, J. K.; Aredo, J. V.; Shaverdashvili, K.; Luo, J.; Carlisle, J. W.; Husain, H.; Muzikansky, A.; Heist, R. S.; Rangachari, D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase II study to evaluate the need for > two doses of nivolumab plus ipilimumab combination (combo) immunotherapy
    Meeting Abstract

    Postow, M. A.; Goldman, D. A.; Shoushtari, A. N.; Warner, A. B.; Callahan, M. K.; Momtaz, P.; Naito, E.; Eton, O.; Nair, S.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Phase Ib trial combining rapid determination of drug-drug interaction (DDI) followed by a dose finding period to assess safety and preliminary efficacy of fimepinostat plus venetoclax in patients with aggressive B-cell lymphoma
    Meeting Abstract

    Phillips, T. J.; De Vos, S.; Westin, J.; Barta, S. K.; Cohen, J. B.; Patel, K.; Smith, S. M.; Pagel, J. M.; Kansra, V.; Grayson, D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Landscape of DNA-damage-repair/homologous recombination deficiency (DDR/HRD) in hepatopancreaticobiliary (HPB) cancers
    Meeting Abstract

    Park, W.; Sokol, E.; Chen, J.; Yu, K. H.; Khalil, D.; Harding, J. J.; El Dika, I. H.; Riaz, N.; Abou-Alfa, G. K.; Kelsen, D. P.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save